CGTX

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for Alzheimer's disease and other neurodegenerative disorders. The company's lead product candidate targets the underlying mechanisms of neurodegeneration rather than just treating symptoms. Cognition Therapeutics focuses on addressing the toxic oligomer hypothesis of Alzheimer's disease through its proprietary drug platform. The company conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates in patients with mild-to-moderate Alzheimer's disease. Cognition Therapeutics collaborates with academic institutions and research organizations to advance its understanding of neurodegenerative processes. The company's research pipeline includes multiple programs aimed at addressing significant unmet medical needs in neurological conditions affecting millions of patients worldwide.